Zogenix, Inc. (NASDAQ:ZGNX)‘s stock had its “buy” rating reaffirmed by investment analysts at Stifel Nicolaus in a report released on Monday, June 26th. They presently have a $26.00 price objective on the stock. Stifel Nicolaus’ target price ...
SmarTrend identified an Uptrend for Zogenix Inc (NASDAQ:ZGNX) on February 9th, 2017 at $9.50. In approximately 5 months, Zogenix Inc has returned 50.00% as of today's recent price of $14.25. In the past 52 weeks, Zogenix Inc …
(Original Source) Shares of Zogenix closed last Friday at $15.22, up $0.24 or 1.60%. ZGNX has a 1-year high of …
In addition to the $35 million acquisition cost in cash and Zogenix stock (11,995,202 shares to be registered), the terms of the purchase agreement includes $50 million in potential regulatory milestone payments and up to $45 million in royalty …
Stock market analysts and brokers have recently amended their target prices on shares of Zogenix, Inc. (ZGNX). According to the latest research reports released, 3 analysts have issued a rating of “buy”, 1 analysts “outperform”, 1 …
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that at the annual general meeting of shareholders held …
SAN DIEGO, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX [FREE Stock Trend Analysis]), a pharmaceutical company developing and commercializing products for the treatment of central nervous system …
Zogenix Inc. (ZGNX) traded on unusually high volume on Aug. 09, as the stock lost 13.77% to close at $10.65. On the day, Zogenix Inc. saw 592,931 shares trade hands on 4,757 trades. Considering that the stock averages only a daily …
Zogenix, Inc. Receives Buy Rating from Stifel Nicolaus - Stock Observer Zogenix, Inc. Runs 2.74 percent For the Week - Concord Register This media report from www.streetinsider.com distributed on June 26, 2017 was a factor to the next …
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zogenix, a specialty pharmaceutical …
AOL3y